Elsevier

European Journal of Cancer

Volume 32, Issue 11, October 1996, Pages 2019-2022
European Journal of Cancer

Short communication
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

https://doi.org/10.1016/0959-8049(96)00226-2Get rights and content

Abstract

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

References (12)

There are more references available in the full text version of this article.

Cited by (52)

  • The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations

    2012, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    Based upon its favorable preclinical activity, apaziquone was selected for clinical evaluation and formulated for intravenous administration [4]. However, no clinical responses were documented in the subsequent phase II clinical trials [6,7]. Most probably, the rapid elimination [5] and relatively poor penetration of the drug compromised drug delivery to tumors following systemic administration [16].

  • Bioreductive Drugs: from Concept to Clinic

    2007, Clinical Oncology
    Citation Excerpt :

    Initial phase I studies of the synthetic MMC analogue EO9 showed no bone marrow toxicity and rapid clearance of EO9; the most important toxicity was proteinuria [173,174]. Phase II studies confirmed the toxicity findings, but the drug did not have any activity as a single agent in a range of tumour types [175,176]. This underlines the need to carry out combination studies when trialling a bioreductive drug.

View all citing articles on Scopus
View full text